Evidence map›Paper›PMID 38709458›Full record

ArticleMolecular diversity2025

Development of novel nitric oxide production inhibitors based on the 7H-pyrrolo[2,3-d]pyrimidine scaffold.

Jie Zhang, Xin Xie, Tingsheng Qin, Hualiang Yao, Zhen Ling, Fengyuan Deng, Xiaoyang Yue, Linhong He

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jie Zhang *Pharmaceutical College, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi, China.
Xin Xie *Pharmaceutical College, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi, China.
Tingsheng QinPharmaceutical College, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi, China.
Hualiang YaoPharmaceutical College, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi, China.
Zhen LingPharmaceutical College, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi, China.
Fengyuan DengCollege of Basic Medical Science, Key Laboratory of Basic Research on Regional Diseases, Guangxi Medical University, Guangxi, China.
Xiaoyang YueCollege of Basic Medical Science, Key Laboratory of Basic Research on Regional Diseases, Guangxi Medical University, Guangxi, China. yue2830827@hotmail.com.
Linhong HePharmaceutical College, Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning, Guangxi, China. HLhongedu@163.com.

Funding

National Natural Science Foundation of China 82260673Natural Science Foundation of Guangxi 2021GXNSFBA075028Natural Science Foundation of Guangxi 2022GXNSFBA035470
6 · The paper itself

Abstract

Nitric oxide (NO), the smallest signaling molecule known, can be excessively produced by overexpressed inducible nitric oxide synthase (iNOS), and eventually leads to multiple inflammatory related diseases. Thus, reducing the overexpression of NO represents as very potential anti-inflammatory strategy. In current study, a series of compounds were designed and synthesized based on the hybridization of 7H-pyrrolo[2,3-d]pyrimidine and cinnamamide fragments in order to develop novel NO production inhibitors. Among them, compound S2h displayed a vigorous inhibitory activity on NO production with an IC

Indexed as

Anti-Inflammatory AgentsEnzyme InhibitorsNitric OxidePyrimidinesPyrrolesAnimalsCarrageenanEdemaMaleMiceMolecular Docking SimulationNitric Oxide Synthase Type IIStructure-Activity RelationshipAnti-Inflammatory AgentsCarrageenanEnzyme InhibitorsNitric OxideNitric Oxide Synthase Type IIPyrimidinesPyrrolesAnti-inflammationCinnamamideiNOSNORAW264.7 cell

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.